Human Longevity, Inc. Announces Promotions and Additions to Leadership Team
Kenneth Bloom, M.D. is President and Ashley Van Zeeland, Ph.D. is Chief Technology Officer, Insurance Industry Leader Tom Wamberg Hired to Head Insurance and Corporate Sales Group
(SAN DIEGO, CA)—April 6, 2016—Human Longevity, Inc. (HLI), the genomics-based, technology-driven company working to revolutionize the practice of medicine, announced today several key promotions and additions to the company’s senior leadership team.
Kenneth Bloom, M.D., will now assume the role of President of HLI. Bloom joined the company to head the oncology product area and to oversee laboratory operations. He will continue to oversee these areas and will lead all product development and commercialization as well as laboratory functions and operations. He reports directly to J. Craig Venter, Ph.D., HLI Co-founder and CEO.
Ashley Van Zeeland, Ph.D., who joined HLI after the company’s acquisition of Cypher Genomics, will now serve as Chief Technology Officer. In this role she will lead the development and commercialization of all software and database products and continue to enhance and refine the commercial genomic pipeline for HLI. Since joining HLI in November, Van Zeeland has been focused on leading the pediatric and rare disease group at HLI as well as integrating the Cypher software into HLI.
Tom Wamberg has joined HLI as President of the company’s Insurance and Corporate Business Group.
“HLI’s comprehensive suite of products and services are rapidly moving into the marketplace for a wide range of customers. As HLI has grown and evolved we are continuously striving to bring new expertise and top talent into the company as our products are commercialized. With Ken and Ashley moving into their new roles and with the addition of Tom, we are confident in our paths to commercialization and in our abilities to bring our vision for genomic-driven healthcare to reality,” said J. Craig Venter, Ph.D., Co-founder and CEO, HLI.
Kenneth Bloom, M.D.
Dr. Bloom has more than 30 years of clinical and business experience and has been an early adopter and big proponent of information technology to revolutionize pathology and other areas of medicine. He is also a prolific and renowned researcher and lecturer in pathology, cancer, telemedicine, and informatics. He comes to HLI most recently from GE Healthcare where he was since 2011 as Chief Medical Officer, In Vitro Diagnostics, Life Sciences. There he had oversight of Medical Affairs, Clinical Pathology Services, Pharma Pathology Services, Bioinformatics and Research and Development. He was also President and CEO of Clarient Pathology Services, the professional group contracted to provide pathology services to Clarient Diagnostic Services and SeqWright. In these roles he led the overall development and execution of the medical and scientific strategy, aligning them with the overall GE mission and business strategy. Prior to Clarient, Dr. Bloom was with US Labs where he was Senior Medical Director since 2002. In addition to Dr. Bloom’s extensive business experience, he has held a series of impressive academic medical posts including Clinical Professor of Pathology at University of Southern California, Keck School of Medicine; and Associate Professor of Pathology at Rush Medical College. Dr. Bloom received his M.D. from Rush Medical College and his B.A. from Grinnell College.
Ashley Van Zeeland
Dr. Van Zeeland joined HLI as part of the acquisition of Cypher Genomics, a leading genome interpretation company, where she was co-founder and CEO. Prior to founding Cypher Genomics, she served as Director, Strategic Partnerships at the Scripps Translational Science Institute where she focused on novel public-private partnerships to accelerate translational research. Before transitioning to her role as Director, Strategic Partnerships she was a research fellow at the Scripps Translational Science Institute working on multiple projects leveraging human genome sequencing to identify disease causative variants and biomarker signatures for various conditions. Dr. Van Zeeland has significant experience leading innovative scientific programs, including groundbreaking work in the genetics of autism, neurodevelopmental disorders and other rare genetic pediatric diseases. She received a Ph.D. in Neuroscience from the University of California, Los Angeles and MBA from the University of California, San Diego.
Wamberg is President, Insurance and Self-Insured Business Unit, at HLI. In his role, he will shape and direct HLI products such as whole genome and whole exome reports, as well as the HLI Health Nucleus, as offerings that insurance companies can bring to their clients. He will also be working with self-insured companies to offer whole genome, whole exome and Health Nucleus as benefits to their employees. In his 30-year career, Wamberg has built and led numerous financial and professional insurance services businesses. Wamberg comes to HLI most recently from Uniphy Health, a secure healthcare collaboration platform for physicians, a company he co-founded in 2013 and where he remains its Chairman. He previously started and led as Chairman and CEO two other consulting companies, Clark & Wamberg, LLC and Clark Inc. Wamberg is a member of the American College of Healthcare Executives, and is a past president of the Association for Advanced Life Underwriting. He has also been past president of the 25 Million-Dollar Forum, chairman of the Legislative Task Force and Nonqualified Benefit Plan committee, and has served as a member of the American Society of Pension Actuaries and the Financial Accounting Standards Board. Wamberg is also the author of three books covering various aspects of the insurance industry. He received his B.S. from Baldwin Wallace University.
About Human Longevity, Inc™
Human Longevity, Inc. (HLI) is the genomics-based, technology-driven company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries to revolutionize the practice of medicine. HLI’s business also includes the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health. For more information, please visit https://www.humanlongevity.com or https://www.healthnucleus.com.